MisinformationPROTECT-LNCT07518914
Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa ( PROTECT-L)
A study testing Diabetes information and Enhanced inoculation message in people with Misinformation and Lenacapavir, run by University of Pennsylvania at 1 site in South Africa.
Trial summary
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. Read more about this study
- Who is it for?
- Ages 18 to 29 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Misinformation, Lenacapavir
- What is being tested?
- Diabetes information and Enhanced inoculation message
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,500 participants
- Where
- 1 siteSouth Africa
- Study dates
- 19 May 2026to Apr 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 29 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Female (cisgender or transgender)
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide consent
- Able to read and understand English
Who cannot join
- Unwilling or unable to provide consent for study participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Alison Buttenheim, PhD contact
South Africa1 site, 1 recruiting
- Recruiting
Health Economics and Epidemiology Research Office, University of the Witwatersrand
Johannesburg
Candice Chetty-Makkan, PhD, +27 (0) 10 001 7941, cchetty@heroza.org
About this study
Official title: Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.
Primary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
- Conditions
- Misinformation, Lenacapavir
- Being tested
- Diabetes information, Enhanced inoculation message
- Keywords
- South Africa, Lenacapavir, Adolescent Girls and Young WOmen, PrEP
- Medical subject headings
- Communication
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diabetes informationBehavioural
Participants enrolled in the control group will receive unrelated information on diabetes topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study
Enhanced inoculation messageBehavioural
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending Lenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.
| Study group | Role | What they receive |
|---|---|---|
| Control | Active comparator | Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study Receives: Behavioral: Diabetes information |
| Enhanced inoculation message | Other | Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impendingLlenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime Receives: Behavioral: Enhanced inoculation message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lenacapavir intention, at the end of the baseline assessment
Intention to get the Lenacapavir, measured after inoculation intervention and misinformation exposure The intention to get Lenacapavir will be measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action.
Measured: At the end of the baseline assessment
Secondary outcomes (33)
Lenacapavir intention, follow-up
Intention to get Lenacapavir, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action.
Measured: 2-4 weeks
Recommend to friends, at the end of the baseline assessment
Intention to recommend Lenacapavir to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action.
Measured: At the end of the baseline assessment
Recommend to friends, follow-up
Intention to recommend Lenacapavir to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action.
Measured: 2-4 weeks
Credibility of inoculated exposure #1
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #2
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #3
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #4
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #5
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #6
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: At the end of the baseline assessment
Credibility of inoculated exposure #7,follow-up
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: 2-4 weeks
Credibility of inoculated exposure #8,follow-up
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim ,for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: 2-4 weeks
Credibility of inoculated exposure #9,follow-up
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: 2-4 weeks
Credibility of inoculated exposure #10,follow-up
Extent to which the claim is credible, extent to which the claim makes you anxious or nervous about Lenacapavir, likelihood of your sharing the claim, for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you believe the claim is real.
Measured: 2-4 weeks
Anxiousness of inoculated exposure #1
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #2
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #3
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #4
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #5
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #6
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: At the end of the baseline assessment
Anxiousness of inoculated exposure #7,follow-up
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: 2-4 weeks
Anxiousness of inoculated exposure #8,follow-up
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: 2-4 weeks
Anxiousness of inoculated exposure #9,follow-up
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: 2-4 weeks
Anxiousness of inoculated exposure #10,follow-up
Extent to which the claim makes you anxious or nervous about lenacapavir for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means the claim makes you anxious or worried.
Measured: 2-4 weeks
Shareability of inoculated exposure #1
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #2
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #3
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #4
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #5
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #6
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: At the end of the baseline assessment
Shareability of inoculated exposure #7,follow-up
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: 2-4 weeks
Shareability of inoculated exposure #8,follow-up
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: 2-4 weeks
Shareability of inoculated exposure #9,follow-up
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: 2-4 weeks
Shareability of inoculated exposure #10,follow-up
Likelihood of your sharing the claim for for the main lenacapavir claims specifically inoculated against and five new claims. All measured on a 1-7 scale. Higher score means you are more likely to share the claim.
Measured: 2-4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Apr 2026
- Study start19 May 2026
- Primary completionApr 2028 (estimated)
- Study completionApr 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MisinformationStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Collaborators
- Health Economics and Epidemiology Research Office, University of the Witwatersrand, University of Cape Town
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07518914
- Sponsor's protocol ID
- 859478
- Acronym
- PROTECT-L
- Status last verified
- Oct 2026
- First submitted
- 1 Apr 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Protecting Against Lenacapavir Misinformation With Young Women in Gauteng, South Africa
- ClinicalTrials.gov ID
- NCT07518914
- Acronym / sponsor ID
- PROTECT-L / 859478
- Conditions
- Misinformation, Lenacapavir
- Keywords
- South Africa, Lenacapavir, Adolescent Girls and Young WOmen, PrEP
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Collaborators
- Health Economics and Epidemiology Research Office, University of the Witwatersrand, University of Cape Town
- Study start
- 19 May 2026 (actual)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Apr 2029 (estimated)
- First posted
- 9 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adolescent girls and young women (AGYW) in South Africa remain disproportionately affected by HIV, with prevalence among 15-24-year-olds at 9.4% in 2024 despite expanded access to condoms, HIV testing, and oral PrEP. While oral PrEP is effective, its reliance on daily adherence and regular follow-up has limited impact for many young women. Lenacapavir (LEN), the first long-acting injectable PrEP administered twice yearly, offers a promising alternative that could improve persistence and protection. However, LEN's potential may be undermined by misinformation, particularly around safety and trust, which has been shown in other HIV prevention contexts to reduce uptake and demand. Proactive strategies, such as psychological inoculation, are therefore needed to prebunk misinformation and support future LEN implementation among AGYW.
Primary objective: To compare changes in intentions to receive Lenacapavir following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about Lenacapavir in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | Active comparator | Behavioral: Diabetes informationParticipants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study |
| Enhanced inoculation message | Other | Behavioral: Enhanced inoculation messageParticipants enrolled in the enhanced inoculation message arm will receive messages that warn them about impendingLlenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime |
Who may qualify
- Ages
- 18 to 29 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Female (cisgender or transgender)
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide consent
Key exclusion criteria (1 listed)
- Unwilling or unable to provide consent for study participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diabetes informationParticipants enrolled in the control group will receive unrelated information on diabetes topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study | Behavioural | Control |
| Enhanced inoculation messageParticipants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending Lenacapavir misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. | Behavioural | Enhanced inoculation message |
Primary outcome
Lenacapavir intention, at the end of the baseline assessment
Time frame: At the end of the baseline assessment
Intention to get the Lenacapavir, measured after inoculation intervention and misinformation exposure The intention to get Lenacapavir will be measured on a 1-10 scale. Higher score meaning you are extremely likely to do the action.
33 secondary outcomes
Lenacapavir intention, follow-up
Time frame: 2-4 weeks
Recommend to friends, at the end of the baseline assessment
Time frame: At the end of the baseline assessment
Recommend to friends, follow-up
Time frame: 2-4 weeks
Credibility of inoculated exposure #1
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #2
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #3
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #4
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #5
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #6
Time frame: At the end of the baseline assessment
Credibility of inoculated exposure #7,follow-up
Time frame: 2-4 weeks
Credibility of inoculated exposure #8,follow-up
Time frame: 2-4 weeks
Credibility of inoculated exposure #9,follow-up
Time frame: 2-4 weeks
Credibility of inoculated exposure #10,follow-up
Time frame: 2-4 weeks
Anxiousness of inoculated exposure #1
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #2
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #3
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #4
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #5
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #6
Time frame: At the end of the baseline assessment
Anxiousness of inoculated exposure #7,follow-up
Time frame: 2-4 weeks
Anxiousness of inoculated exposure #8,follow-up
Time frame: 2-4 weeks
Anxiousness of inoculated exposure #9,follow-up
Time frame: 2-4 weeks
Anxiousness of inoculated exposure #10,follow-up
Time frame: 2-4 weeks
Shareability of inoculated exposure #1
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #2
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #3
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #4
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #5
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #6
Time frame: At the end of the baseline assessment
Shareability of inoculated exposure #7,follow-up
Time frame: 2-4 weeks
Shareability of inoculated exposure #8,follow-up
Time frame: 2-4 weeks
Shareability of inoculated exposure #9,follow-up
Time frame: 2-4 weeks
Shareability of inoculated exposure #10,follow-up
Time frame: 2-4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: Undecided. The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Related trials for Misinformation
Not yet recruiting
Development and Evaluation of a Digital Educational Intervention to Improve Vaccine Confidence and Communication Among Registered Nurses: Protocol for a Randomized Controlled Trial (VaxNurse-RCT).
Vaccine Hesitancy, Vaccine Acceptance
Recruiting
Building Cognitive Resilience to Vaccine Misinformation Using AI in Europe
Healthy
Active, not recruiting
Protecting Against HIV Vaccine Misinformation With Adolescent Girls and Young Women in South Africa
Misinformation, HIV Vaccine
Not yet recruiting
Social Media Withdrawal in Pregnancy: Effects on Maternal Mental Health and Misinformation
Pregnancy
Not yet recruiting
Cognitive and Emotional Inoculation Against Nutrition-Related Misinformation in Young Adults
Health Misinformation, Misinformation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alison Buttenheim, PhD contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diabetes information and Enhanced inoculation message in people with Misinformation and Lenacapavir, run by University of Pennsylvania at 1 site in South Africa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Teniola Egbe, MPH, MBE (215-898-2939, tegbe@pennmedicine.upenn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lenacapavir intention, at the end of the baseline assessment (time frame: At the end of the baseline assessment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.